Our novel class of highly selective small molecules are advancing in indications of immuno and cardio metabolic dysfunction. We are committed to better solution for people living with Diabetes, Obesity, Liver disease  and associated immuno and cardio-metabolic conditions.

Our molecule acts as a glycemic rheostat auto adjusting sugar levels. We have compelling data across multiple animal models for Diabetes, Obesity and associated immuno- metabolic disease complications.

We discovered several novel chemistry series generating a broad genus global patent position of issuances for any disease associated with metabolic dysregulation of our multimodal target.